116 related articles for article (PubMed ID: 22169270)
1. Radiogenomics: associations in all the wrong places?
Parliament MB
Lancet Oncol; 2012 Jan; 13(1):7-8. PubMed ID: 22169270
[No Abstract] [Full Text] [Related]
2. Independent validation of genes and polymorphisms reported to be associated with radiation toxicity: a prospective analysis study.
Barnett GC; Coles CE; Elliott RM; Baynes C; Luccarini C; Conroy D; Wilkinson JS; Tyrer J; Misra V; Platte R; Gulliford SL; Sydes MR; Hall E; Bentzen SM; Dearnaley DP; Burnet NG; Pharoah PD; Dunning AM; West CM
Lancet Oncol; 2012 Jan; 13(1):65-77. PubMed ID: 22169268
[TBL] [Abstract][Full Text] [Related]
3. A genome wide association study (GWAS) providing evidence of an association between common genetic variants and late radiotherapy toxicity.
Barnett GC; Thompson D; Fachal L; Kerns S; Talbot C; Elliott RM; Dorling L; Coles CE; Dearnaley DP; Rosenstein BS; Vega A; Symonds P; Yarnold J; Baynes C; Michailidou K; Dennis J; Tyrer JP; Wilkinson JS; Gómez-Caamaño A; Tanteles GA; Platte R; Mayes R; Conroy D; Maranian M; Luccarini C; Gulliford SL; Sydes MR; Hall E; Haviland J; Misra V; Titley J; Bentzen SM; Pharoah PD; Burnet NG; Dunning AM; West CM
Radiother Oncol; 2014 May; 111(2):178-85. PubMed ID: 24785509
[TBL] [Abstract][Full Text] [Related]
4. Finding the genetic determinants of adverse reactions to radiotherapy.
Rattay T; Talbot CJ
Clin Oncol (R Coll Radiol); 2014 May; 26(5):301-8. PubMed ID: 24702740
[TBL] [Abstract][Full Text] [Related]
5. Altered fractionation in radiotherapy: from radiobiological rationale to therapeutic gain.
Marcu LG
Cancer Treat Rev; 2010 Dec; 36(8):606-14. PubMed ID: 20494524
[TBL] [Abstract][Full Text] [Related]
6. Individual patient data meta-analysis shows a significant association between the ATM rs1801516 SNP and toxicity after radiotherapy in 5456 breast and prostate cancer patients.
Andreassen CN; Rosenstein BS; Kerns SL; Ostrer H; De Ruysscher D; Cesaretti JA; Barnett GC; Dunning AM; Dorling L; West CML; Burnet NG; Elliott R; Coles C; Hall E; Fachal L; Vega A; Gómez-Caamaño A; Talbot CJ; Symonds RP; De Ruyck K; Thierens H; Ost P; Chang-Claude J; Seibold P; Popanda O; Overgaard M; Dearnaley D; Sydes MR; Azria D; Koch CA; Parliament M; Blackshaw M; Sia M; Fuentes-Raspall MJ; Ramon Y Cajal T; Barnadas A; Vesprini D; Gutiérrez-Enríquez S; Mollà M; Díez O; Yarnold JR; Overgaard J; Bentzen SM; Alsner J;
Radiother Oncol; 2016 Dec; 121(3):431-439. PubMed ID: 27443449
[TBL] [Abstract][Full Text] [Related]
7. Response to "Unacceptable cosmesis in a protocol investigating intensity-modulated radiotherapy with active breathing control for accelerated partial-breast irradiation" (Int J Radiat Oncol Biol Phys 2010;76:71-78) and "Toxicity of three-dimensional conformal radiotherapy for accelerated partial breast irradiation" Int J Radiat Oncol Biol Phys 2009;75:1290-1296).
Wolmark N; Curran WJ; Vicini F; White J; Costantino JP; Arthur D; Kuske R; Rabinovitch R; Julian TB; Parda DS
Int J Radiat Oncol Biol Phys; 2010 May; 77(1):317; author reply 318. PubMed ID: 20394863
[No Abstract] [Full Text] [Related]
8. Radiation therapy modalities for prostate cancer.
Deville C; Ben-Josef E; Vapiwala N
JAMA; 2012 Aug; 308(5):451; author reply 451-2. PubMed ID: 22851101
[No Abstract] [Full Text] [Related]
9. Radiation therapy modalities for prostate cancer.
Mendenhall NP; Schild S; Slater J
JAMA; 2012 Aug; 308(5):450-1; author reply 451-2. PubMed ID: 22851100
[No Abstract] [Full Text] [Related]
10. Radiation therapy modalities for prostate cancer.
Jacobs BL; Zhang Y; Hollenbeck BK
JAMA; 2012 Aug; 308(5):450; author reply 451-2. PubMed ID: 22851099
[No Abstract] [Full Text] [Related]
11. Intensity-modulated radiotherapy: the gold standard for postprostatectomy irradiation?
Bossi A; De Meerleer G; Ost P
Eur Urol; 2011 Dec; 60(6):1149-50; discussion 1150-1. PubMed ID: 21920662
[No Abstract] [Full Text] [Related]
12. Is proton-beam therapy better than intensity-modulated radiation therapy for prostate cancer?
Kagan AR; Yeh J; Schulz RJ
Am J Clin Oncol; 2014 Dec; 37(6):525-7. PubMed ID: 24577165
[No Abstract] [Full Text] [Related]
13. In regard to Harris et al.
Khosla D; Gupta R; Kumar R
Int J Radiat Oncol Biol Phys; 2013 May; 86(1):5-6. PubMed ID: 23582243
[No Abstract] [Full Text] [Related]
14. Intensity-modulated radiotherapy as primary therapy for prostate cancer: report on acute toxicity after dose escalation with simultaneous integrated boost to intraprostatic lesion.
Fonteyne V; Villeirs G; Speleers B; De Neve W; De Wagter C; Lumen N; De Meerleer G
Int J Radiat Oncol Biol Phys; 2008 Nov; 72(3):799-807. PubMed ID: 18407430
[TBL] [Abstract][Full Text] [Related]
15. Hypofractionated concomitant intensity-modulated radiotherapy boost for high-risk prostate cancer: late toxicity.
Quon H; Cheung PC; Loblaw DA; Morton G; Pang G; Szumacher E; Danjoux C; Choo R; Thomas G; Kiss A; Mamedov A; Deabreu A
Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):898-905. PubMed ID: 21237581
[TBL] [Abstract][Full Text] [Related]
16. Long-term results of a study using individualized planning target volumes for hypofractionated intensity-modulated radiotherapy boost for prostate cancer.
Chu W; Loblaw DA; Chan K; Morton G; Choo R; Szumacher E; Danjoux C; Pignol JP; Cheung P
Radiat Oncol; 2015 Apr; 10():95. PubMed ID: 25903934
[TBL] [Abstract][Full Text] [Related]
17. Outcomes of intensity-modulated radiotherapy for prostate cancer using an empty bladder protocol.
Tuan JK; Ha TC; Ong WS; Siow TR; Tham IW; Ng WL; Wang ML; Chua ET; Tan TW
Clin Oncol (R Coll Radiol); 2012 Nov; 24(9):e137-9. PubMed ID: 22795829
[No Abstract] [Full Text] [Related]
18. Hypofractionated intensity-modulated arc therapy for lymph node metastasized prostate cancer.
Fonteyne V; De Gersem W; De Neve W; Jacobs F; Lumen N; Vandecasteele K; Villeirs G; De Meerleer G
Int J Radiat Oncol Biol Phys; 2009 Nov; 75(4):1013-20. PubMed ID: 19386427
[TBL] [Abstract][Full Text] [Related]
19. Acute radiation-induced nocturia in prostate cancer patients is associated with pretreatment symptoms, radical prostatectomy, and genetic markers in the TGFβ1 gene.
De Langhe S; De Ruyck K; Ost P; Fonteyne V; Werbrouck J; De Meerleer G; De Neve W; Thierens H
Int J Radiat Oncol Biol Phys; 2013 Feb; 85(2):393-9. PubMed ID: 22658438
[TBL] [Abstract][Full Text] [Related]
20. Assessment of external beam radiation technology for dose escalation and normal tissue protection in the treatment of prostate cancer.
D'Ambrosio DJ; Pollack A; Harris EE; Price RA; Verhey LJ; Roach M; Demanes DJ; Steinberg ML; Potters L; Wallner PE; Konski A
Int J Radiat Oncol Biol Phys; 2008 Mar; 70(3):671-7. PubMed ID: 18262085
[No Abstract] [Full Text] [Related]
[Next] [New Search]
